Feature | Radiation Oncology | October 04, 2016 | By Michael V. Knopp, M.D., Ph.D., Chadwick L. Wright, M.D., Ph.D., Katherine Binzel, Ph.D. and Jun Zhang, Ph.D.

Precision PET Imaging to Advance Personalized Cancer Management

New cPET and dPET technologies and methodologies will contribute to the goals of precision medicine and will further expand the clinical utilization of PET

PET imaging
PET imaging

Precision medicine is not only a buzzword, it is a call to action to radically advance our capabilities in the era of molecular targeted medicine. Positron emission tomography (PET) has firmly established its leading role as a capable oncologic molecular imaging technique over the last two decades, however its technological advances have been modest at best.

An essential capability of a methodology to support precision medicine with the goal of being tailored to the individual patient and disease characteristics is that such a methodology is a valid biomarker and ideally enables consistent and accurate quantitative readouts. This is an area where PET imaging has been challenged and limited not due to inherent inabilities, but more due to technological limitations. 

 

Technological Challenges

In the days of bragging rights on how many megapixels one’s smartphone has, PET imaging has been lagging behind other cross-sectional imaging methodologies in its ability to improve the precision of the detector chain and the resulting image quality. While computed tomography (CT) imaging is done routinely at cross-sectional image matrixes of 512 x 512, PET imaging has remained nearly unchanged over the last two decades at matrix sizes of 144 x 144 to 200 x 200. This fact gives an insight into some of the technological challenges of conventional PET (cPET) technology. 

Another challenge for PET has been the lack of harmonization in acquisition procedures, post-processing and semi- or even quantitative assessment approaches. While considerable progress has been made based on best practices and regulatory and scientific recommendations, variabilities are still largely jeopardizing the robust evolution of PET as a noninvasive, molecular-based technique to enable precision medicine. 

 

Opportunities

Today, radiomics and big data are emerging and highly visible efforts that require precise, high-quality imaging to deliver on this promise of personalized medicine. These big imaging data opportunities are being further nurtured by the availability of decentralized and increasingly cloud-based computational capabilities. Another increasingly important opportunity for PET is its role as a companion diagnostic in the area of tissue markers or genetic profile-driven therapies, as well as its evolving role into integrated theranostic approaches. With such promising and exciting prospects, the introduction and clinical integration of new technologies can drive new PET imaging paradigms.

An essential and increasingly accepted PET technology advance has been the refinement of time-of-flight (TOF). This helps to reduce the uncertainty of the true three-dimensional location of the PET isotope annihilation event and thus more precisely localize radiotracer uptake within the body. Current TOF cPET systems can now be improved through the introduction of higher definition reconstructions from the standard definition (SD) PET imaging which uses image matrix sizes of up to 200 x 200, to high definition (HD) of up to 400 x 400, thus reducing the reconstructed cPET image voxel volumes from ~64 mm3 to ~8 mm3. Figure 1 presents a whole-body FDG cPET image using the default SD reconstruction and the new HD reconstruction of the same dataset. The image comparison highlights a visually sharper HD image that has less partial volume effect and more accurate quantification and contributes to improved overall imaging precision.

The backbone of cPET has been photomultiplier tube-based detector technology that requires Anger logic to appropriately detect and localize the coincident annihilation photons. This is then processed using analog signal technologies. A recent technical advance that was predominately driven to enable clinical PET/MR was the introduction of solid-state, silicon-based photomultipliers with analog signal processing technologies. The most recent advance is the introduction of solid-state, digital photon counting (DPC) PET detectors and the replacement of analog signal processing, which enables a fully integrated digital detection and processing chain with markedly improved TOF timing resolution.

Our team is conducting pre-clinical and clinical trials using a pre-commercial release fully DPC-based PET (dPET) system that consistently provides 325 ps TOF timing resolution (Vereos Digital PET/CT, Philips). It also enables even higher-definition imaging using reconstruction voxel sizes of 1 mm3 with an ultra high-definition (UHD) reconstruction approach. Figure 2 presents an intra-individual comparison of a FDG whole-body PET scan performed back to back between a SD cPET and an UHD dPET. 

 

Expanding Clinical Utilization

The current observations in the ongoing clinical trials with cPET and dPET already indicate that these new technologies and methodologies will significantly contribute to the goals of precision medicine and will further expand the clinical utilization of PET to be a clinically even more useful biomarker to guide the management of personalized oncologic therapies.

 

Michael V. Knopp, M.D., Ph.D., coordinating author, is professor of radiology and Novartis chair of imaging research, principal investigator and director, Wright Center of Innovation in Biomedical Imaging and the Ohio Imaging Research and Innovation Network. He is also vice chair of research for the Department of Radiology at The Ohio State University Wexner Medical Center.

Related Content

NIH Study of Brain Energy Patterns Provides New Insights into Alcohol Effects

NIH scientists present a new method for combining measures of brain activity (left) and glucose consumption (right) to study regional specialization and to better understand the effects of alcohol on the human brain. Image courtesy of Ehsan Shokri-Kojori, Ph.D., of NIAAA.

News | Neuro Imaging | March 22, 2019
March 22, 2019 — Assessing the patterns of energy use and neuronal activity simultaneously in the human brain improve
Improving Molecular Imaging Using a Deep Learning Approach
News | Nuclear Imaging | March 21, 2019
Generating comprehensive molecular images of organs and tumors in living organisms can be performed at ultra-fast speed...
PET Scans Show Biomarkers Could Spare Some Breast Cancer Patients from Chemotherapy
News | PET Imaging | March 18, 2019
A new study positron emission tomography (PET) scans has identified a biomarker that may accurately predict which...
Researchers Create New Method for Developing Cancer Imaging Isotopes

Prototype fluidic system for zirconium-89 purification. Image taken through a hot cell window at the Department of Radiology, University of Washington. Image courtesy of Matthew O’Hara, Pacific Northwest National Laboratory

News | Radiopharmaceuticals and Tracers | March 14, 2019
A team of researchers at the University of Washington announced they developed a new automated system for producing...
Mississippi Cancer Center Combines RayStation and TomoTherapy for Prostate Cancer Case
News | Treatment Planning | March 08, 2019
Anderson Regional Cancer Center in Meridian, Miss., has treated its first patient using the combination of RaySearch's...
Siemens Healthineers Announces First U.S. Install of Biograph Vision PET/CT
News | PET-CT | March 06, 2019
Siemens Healthineers’ new Biograph Vision positron emission tomography/computed tomography (PET/CT) system has been...
Videos | Proton Therapy | February 28, 2019
ITN Associate Editor Jeff Zagoudis speaks with ...
360_NW_Proton_Center_Inclined_Room_THUMBNAIL
360 Photos | 360 View Photos | February 28, 2019
This is a 360 view of Treatment Room 3 (of 4) at the N...